At the time of writing, Apellis Pharmaceuticals Inc [APLS] stock is trading at $23.8, up 2.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APLS shares have gain 6.39% over the last week, with a monthly amount drifted -16.93%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on September 26, 2025, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $18 for it. Previously, Raymond James downgraded its rating to Outperform on May 09, 2025, and kept the price target unchanged to $52. On May 09, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $23 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $44 on April 29, 2025. Goldman downgraded its rating to a Neutral but $36 remained the price target by the analyst firm on December 17, 2024. Morgan Stanley started tracking with a Equal-Weight rating for this stock on November 21, 2024, and assigned it a price target of $31. In a note dated October 25, 2024, RBC Capital Mkts initiated an Sector Perform rating and provided a target price of $25 on this stock.
For the past year, the stock price of Apellis Pharmaceuticals Inc fluctuated between $16.10 and $35.72. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $23.8 at the most recent close of the market. An investor can expect a potential drop of -15.97% based on the average APLS price forecast.
Analyzing the APLS fundamentals
According to Apellis Pharmaceuticals Inc [NASDAQ:APLS], the company’s sales were 754.65M for trailing twelve months, which represents an -10.61% plunge. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.25%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.16 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.27 points at the first support level, and at 22.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.14, and for the 2nd resistance point, it is at 24.47.
Ratios To Look Out For
It is important to note that Apellis Pharmaceuticals Inc [NASDAQ:APLS] has a current ratio of 3.77. As well, the Quick Ratio is 3.16, while the Cash Ratio is 1.85. Considering the valuation of this stock, the price to sales ratio is 3.98, the price to book ratio is 19.21.
Transactions by insiders
Recent insider trading involved Dunlop A. Sinclair, Director, that happened on Sep 30 ’25 when 31092.0 shares were sold. Director, Dunlop A. Sinclair completed a deal on Sep 19 ’25 to sell 31092.0 shares. Meanwhile, Director Dunlop A. Sinclair bought 93276.0 shares on Sep 19 ’25.
